Product Code: GVR-4-68039-960-0
Veterinary Biomarkers Market Summary
The global veterinary biomarkers market size was valued at USD 1.1 billion in 2025 and is projected to grow from USD 1.2 billion in 2026 to USD 2.6 billion by 2033, at a CAGR of 12.1% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 33.0% in 2025. The increasing prevalence of chronic conditions such as cancer and cardiovascular diseases in animals is significantly increasing the demand for biomarker-based assay diagnostic kits in veterinary applications to predict disease in its early stages.
Global Veterinary Biomarkers Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global veterinary biomarkers market report based on animal, product, application, disease type, end use, and region:
- Animal Outlook (Revenue, USD Million, 2021 - 2033)
- Companion Animals
- Production Animals
- Cattle
- Pigs
- Poultry
- Others
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Biomarkers, Kits & Reagents
- Instruments
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Disease Diagnostics
- Preclinical Research
- Others
- Disease Type Outlook (Revenue, USD Million, 2021 - 2033)
- Inflammatory & Infectious Diseases
- Cardiovascular Diseases
- Musculoskeletal Diseases
- Oncology
- Others
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Veterinary Diagnostic Laboratories
- Veterinary Hospitals & Clinics
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin America
- Middle East & Africa
- South Africa
- UAE
- Saudi Arabia
- Kuwait
- Qatar
- Oman
Table of Contents
Chapter 1. Research Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Animal
- 1.2.2. Product
- 1.2.3. Application
- 1.2.4. Disease Type
- 1.2.5. End Use
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
- 1.5. Information or Data Analysis
- 1.5.1. Data Analysis Models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity Flow Analysis
- 1.7.2. Top-Down Analysis
- 1.7.3. Bottom-up Approach
- 1.7.4. Multivariate Analysis
- 1.8. List Of Secondary Sources
- 1.9. List Of Abbreviations
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Rising Prevalence of Cardiac Diseases in Companion Animals
- 3.2.1.2. Growing Adoption of Precision Veterinary Medicine and Companion Diagnostics
- 3.2.1.3. Increasing R&D Investments and Technological Advancements in Veterinary Diagnostics
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. High Cost of Biomarker Development and Advanced Diagnostic Testing
- 3.2.2.2. Limited Standardization and Regulatory Challenges
- 3.2.3. Market Opportunity Analysis
- 3.2.4. Market Challenge Analysis
- 3.3. Technology Landscape
- 3.4. Pricing Model Analysis, 2025
- 3.5. Tariff Impact Analysis
- 3.6. Estimated Animal Population, By Key Countries & Key Species, 2021-2025
- 3.7. Market Analysis Tools
- 3.7.1. Porter's Five Force Analysis
- 3.7.2. PESTEL Analysis
Chapter 4. Veterinary Biomarkers Market: Animal Estimates & Trend Analysis
- 4.1. Veterinary Biomarkers Market, By Animal: Segment Dashboard
- 4.2. Veterinary Biomarkers Market, By Animal: Movement Analysis
- 4.3. Veterinary Biomarkers Market Estimates & Forecasts, By Animal, 2021 - 2033 (USD Million)
- 4.4. Companion Animals
- 4.4.1. Companion Animals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.2. Dogs
- 4.4.2.1. Dogs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.3. Cats
- 4.4.3.1. Cats Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.4. Horses
- 4.4.4.1. Horses Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4.5. Others
- 4.4.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5. Production Animals
- 4.5.1. Production Animals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5.2. Cattle
- 4.5.2.1. Cattle Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5.3. Pigs
- 4.5.3.1. Pigs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5.4. Poultry
- 4.5.4.1. Poultry Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5.5. Others
- 4.5.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Veterinary Biomarkers Market: Product Estimates & Trend Analysis
- 5.1. Veterinary Biomarkers Market, By Product: Segment Dashboard
- 5.2. Veterinary Biomarkers Market, By Product: Movement Analysis
- 5.3. Veterinary Biomarkers Market Estimates & Forecasts, By Product, 2021 - 2033 (USD Million)
- 5.4. Biomarkers, Kits & Reagents
- 5.4.1. Biomarkers, Kits & Reagents Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Instruments
- 5.5.1. Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Veterinary Biomarkers Market: Application Estimates & Trend Analysis
- 6.1. Veterinary Biomarkers Market, By Application: Segment Dashboard
- 6.2. Veterinary Biomarkers Market, By Application: Movement Analysis
- 6.3. Veterinary Biomarkers Market Estimates & Forecasts, By Application, 2021 - 2033 (USD Million)
- 6.4. Disease Diagnostics
- 6.4.1. Disease Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Preclinical Research
- 6.5.1. Preclinical Research Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6. Others
- 6.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Veterinary Biomarkers Market: Disease Type Estimates & Trend Analysis
- 7.1. Veterinary Biomarkers Market, By Disease Type: Segment Dashboard
- 7.2. Veterinary Biomarkers Market, By Disease Type: Movement Analysis
- 7.3. Veterinary Biomarkers Market Estimates & Forecasts, By Disease Type, 2021 - 2033 (USD Million)
- 7.4. Inflammatory & Infectious Diseases
- 7.4.1. Inflammatory & Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Cardiovascular Diseases
- 7.5.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Musculoskeletal Diseases
- 7.6.1. Musculoskeletal Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7. Oncology
- 7.7.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8. Others
- 7.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Veterinary Biomarkers Market: End Use Estimates & Trend Analysis
- 8.1. Veterinary Biomarkers Market, By End Use: Segment Dashboard
- 8.2. Veterinary Biomarkers Market, By End Use: Movement Analysis
- 8.3. Veterinary Biomarkers Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
- 8.4. Veterinary Diagnostic Laboratories
- 8.4.1. Veterinary Diagnostic Laboratories Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5. Veterinary Hospitals & Clinics
- 8.5.1. Veterinary Hospitals & Clinics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6. Others
- 8.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Veterinary Biomarkers Market: Regional Estimates & Trend Analysis
- 9.1. Regional Market Dashboard
- 9.2. Regional Market Share Analysis, 2025 & 2033
- 9.3. North America
- 9.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.3.2. U.S
- 9.3.2.1. Key Country Dynamics
- 9.3.2.2. Competitive Scenario
- 9.3.2.3. Regulatory Framework
- 9.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.3.3. Canada
- 9.3.3.1. Key Country Dynamics
- 9.3.3.2. Competitive Scenario
- 9.3.3.3. Regulatory Framework
- 9.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.3.4. Mexico
- 9.3.4.1. Key Country Dynamics
- 9.3.4.2. Competitive Scenario
- 9.3.4.3. Regulatory Framework
- 9.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4. Europe
- 9.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.2. UK
- 9.4.2.1. Key Country Dynamics
- 9.4.2.2. Competitive Scenario
- 9.4.2.3. Regulatory Framework
- 9.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.3. Germany
- 9.4.3.1. Key Country Dynamics
- 9.4.3.2. Competitive Scenario
- 9.4.3.3. Regulatory Framework
- 9.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.4. France
- 9.4.4.1. Key Country Dynamics
- 9.4.4.2. Competitive Scenario
- 9.4.4.3. Regulatory Framework
- 9.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.5. Italy
- 9.4.5.1. Key Country Dynamics
- 9.4.5.2. Competitive Scenario
- 9.4.5.3. Regulatory Framework
- 9.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.6. Spain
- 9.4.6.1. Key Country Dynamics
- 9.4.6.2. Competitive Scenario
- 9.4.6.3. Regulatory Framework
- 9.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.7. Denmark
- 9.4.7.1. Key Country Dynamics
- 9.4.7.2. Competitive Scenario
- 9.4.7.3. Regulatory Framework
- 9.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.8. Sweden
- 9.4.8.1. Key Country Dynamics
- 9.4.8.2. Competitive Scenario
- 9.4.8.3. Regulatory Framework
- 9.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.9. Norway
- 9.4.9.1. Key Country Dynamics
- 9.4.9.2. Competitive Scenario
- 9.4.9.3. Regulatory Framework
- 9.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5. Asia Pacific
- 9.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.2. Japan
- 9.5.2.1. Key Country Dynamics
- 9.5.2.2. Competitive Scenario
- 9.5.2.3. Regulatory Framework
- 9.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.3. China
- 9.5.3.1. Key Country Dynamics
- 9.5.3.2. Competitive Scenario
- 9.5.3.3. Regulatory Framework
- 9.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.4. India
- 9.5.4.1. Key Country Dynamics
- 9.5.4.2. Competitive Scenario
- 9.5.4.3. Regulatory Framework
- 9.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.5. Australia
- 9.5.5.1. Key Country Dynamics
- 9.5.5.2. Competitive Scenario
- 9.5.5.3. Regulatory Framework
- 9.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.6. Thailand
- 9.5.6.1. Key Country Dynamics
- 9.5.6.2. Competitive Scenario
- 9.5.6.3. Regulatory Framework
- 9.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.7. South Korea
- 9.5.7.1. Key Country Dynamics
- 9.5.7.2. Competitive Scenario
- 9.5.7.3. Regulatory Framework
- 9.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6. Latin America
- 9.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6.2. Brazil
- 9.6.2.1. Key Country Dynamics
- 9.6.2.2. Competitive Scenario
- 9.6.2.3. Regulatory Framework
- 9.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6.3. Argentina
- 9.6.3.1. Key Country Dynamics
- 9.6.3.2. Competitive Scenario
- 9.6.3.3. Regulatory Framework
- 9.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.7. MEA
- 9.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.7.2. South Africa
- 9.7.2.1. Key Country Dynamics
- 9.7.2.2. Competitive Scenario
- 9.7.2.3. Regulatory Framework
- 9.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.7.3. UAE
- 9.7.3.1. Key Country Dynamics
- 9.7.3.2. Competitive Scenario
- 9.7.3.3. Regulatory Framework
- 9.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.7.4. Saudi Arabia
- 9.7.4.1. Key Country Dynamics
- 9.7.4.2. Competitive Scenario
- 9.7.4.3. Regulatory Framework
- 9.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.7.5. Kuwait
- 9.7.5.1. Key Country Dynamics
- 9.7.5.2. Competitive Scenario
- 9.7.5.3. Regulatory Framework
- 9.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.7.6. Qatar
- 9.7.6.1. Key Country Dynamics
- 9.7.6.2. Competitive Scenario
- 9.7.6.3. Regulatory Framework
- 9.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.7.7. Oman
- 9.7.7.1. Key Country Dynamics
- 9.7.7.2. Competitive Scenario
- 9.7.7.3. Regulatory Framework
- 9.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 10. Competitive Landscape
- 10.1. Key Participant Categorization
- 10.1.1. Market Leaders
- 10.1.2. Emerging Players
- 10.2. Market Assessment Analysis, 2025 (Heat Map Analysis)
- 10.3. Company Profiles
- 10.3.1. Zoetis
- 10.3.1.1. Company Overview
- 10.3.1.2. Financial Performance
- 10.3.1.3. Product Benchmarking
- 10.3.1.4. Strategic Initiatives
- 10.3.2. Virbac
- 10.3.2.1. Company Overview
- 10.3.2.2. Financial Performance
- 10.3.2.3. Product Benchmarking
- 10.3.2.4. Strategic Initiatives
- 10.3.3. Life Diagnostics
- 10.3.3.1. Company Overview
- 10.3.3.2. Financial Performance
- 10.3.3.3. Product Benchmarking
- 10.3.3.4. Strategic Initiatives
- 10.3.4. ACUVET BIOTECH
- 10.3.4.1. Company Overview
- 10.3.4.2. Financial Performance
- 10.3.4.3. Product Benchmarking
- 10.3.4.4. Strategic Initiatives
- 10.3.5. Merck
- 10.3.5.1. Company Overview
- 10.3.5.2. Financial Performance
- 10.3.5.3. Product Benchmarking
- 10.3.5.4. Strategic Initiatives
- 10.3.6. IDEXX Laboratories, Inc.
- 10.3.6.1. Company Overview
- 10.3.6.2. Financial Performance
- 10.3.6.3. Product Benchmarking
- 10.3.6.4. Strategic Initiatives
- 10.3.7. MI: RNA Diagnostics Ltd.
- 10.3.7.1. Company Overview
- 10.3.7.2. Financial Performance
- 10.3.7.3. Product Benchmarking
- 10.3.7.4. Strategic Initiatives
- 10.3.8. Mercodia AB
- 10.3.8.1. Company Overview
- 10.3.8.2. Financial Performance
- 10.3.8.3. Product Benchmarking
- 10.3.8.4. Strategic Initiatives
- 10.3.9. Antech Diagnostics, Inc.
- 10.3.9.1. Company Overview
- 10.3.9.2. Financial Performance
- 10.3.9.3. Product Benchmarking
- 10.3.9.4. Strategic Initiatives
- 10.3.10. Avacta Animal Health Limited
- 10.3.10.1. Company Overview
- 10.3.10.2. Financial Performance
- 10.3.10.3. Product Benchmarking
- 10.3.10.4. Strategic Initiatives